Literature DB >> 28256449

Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE.

Davut B Hasdemir1, Lukas Aguirre Dávila, Nora Schweitzer, Bernhard C Meyer, Armin Koch, Arndt Vogel, Frank Wacker, Thomas Rodt.   

Abstract

PURPOSE: Transarterial chemoembolization (TACE) is an established treatment for intermediate stage hepatocellular carcinoma (HCC). The aim of this retrospective study was to evaluate the power of lesion vascularization criteria based on computed tomography for prognosis of overall survival before initiation of treatment.
METHODS: A total of 59 patients with intermediate stage HCC treated with TACE as first-line treatment were retrospectively evaluated. TACE procedures were performed using doxorubicin, cisplatin, and lipiodol. Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) were used to determine the initial tumor response. Four vascularization patterns (VP) of the largest target lesion (homogeneous vascularization [VP1], homogeneous vascularization with additional arterial hypervascularization [VP2], heterogeneous vascularization with [VP3] and without zones of hypervascularization [VP4]) were assessed prior to the first TACE and correlated to survival.
RESULTS: Kaplan-Meier analysis yielded a median overall survival of 608 days (standard error [SE], 120.5 days). Survival analysis showed significant differences depending on the vascularization patterns (P = 0.012; hazard ratio, 0.327): patients with homogeneously vascularized lesions (VP1, VP2) had a median overall survival of 1091 days (SE, 235.5 days). Patients with heterogeneous vascularization of the lesion (VP3 and VP4) showed a median overall survival of 508 days (SE, 113.9 days).
CONCLUSION: The vascularization pattern of the largest HCC lesion is helpful for survival prognosis under TACE treatment and therefore has the potential to be used as an additional parameter for treatment stratification.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28256449      PMCID: PMC5411003          DOI: 10.5152/dir.2016.16006

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  29 in total

Review 1.  Loco-regional treatment of hepatocellular carcinoma.

Authors:  Riccardo Lencioni
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 2.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

3.  Chemoembolization for intermediate HCC: is there proof of survival benefit?

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2011-10-17       Impact factor: 25.083

Review 4.  Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.

Authors:  Matteo Cescon; Alessandro Cucchetti; Matteo Ravaioli; Antonio Daniele Pinna
Journal:  J Hepatol       Date:  2012-10-04       Impact factor: 25.083

Review 5.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

Review 6.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

7.  Transarterial chemoembolization - status quo in Germany.

Authors:  C Niessen; P Wiggermann; C Velandia; C Stroszczynski; P L Pereira
Journal:  Rofo       Date:  2013-07-29

8.  Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization.

Authors:  MingDe Lin; Olivier Pellerin; Nikhil Bhagat; Pramod P Rao; Romaric Loffroy; Roberto Ardon; Benoit Mory; Diane K Reyes; Jean-François Geschwind
Journal:  J Vasc Interv Radiol       Date:  2012-12       Impact factor: 3.464

9.  Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma.

Authors:  Peng Wang; Lili Sheng; Guoxiang Wang; Heping Wang; Xinyu Huang; Xiaoxing Yan; Xiaohua Yang; Renguang Pei
Journal:  Mol Clin Oncol       Date:  2014-01-07

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  3 in total

1.  Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.

Authors:  Johanna Maria Mijntje van Breugel; Jean-François Geschwind; Sahar Mirpour; Lynn Jeanette Savic; Xuchen Zhang; Rafael Duran; MingDe Lin; Milena Miszczuk; Eleni Liapi; Julius Chapiro
Journal:  Theranostics       Date:  2019-05-27       Impact factor: 11.556

2.  Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma.

Authors:  Yanmei Dai; Huijie Jiang; Shi-Ting Feng; Yuwei Xia; Jinping Li; Sheng Zhao; Dandan Wang; Xu Zeng; Yusi Chen; Yanjie Xin; Dongmin Liu
Journal:  J Hepatocell Carcinoma       Date:  2022-04-05

3.  Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer.

Authors:  Milena A Miszczuk; Julius Chapiro; Jean-Francois H Geschwind; Vinayak Thakur; Nariman Nezami; Fabian Laage-Gaupp; Michal Kulon; Johanna M M van Breugel; Arash Fereydooni; MingDe Lin; Lynn Jeanette Savic; Bruno Tegel; Tamara Wahlin; Eliot Funai; Todd Schlachter
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.